AnaptysBio, Inc.
Antibodies Directed Against Programmed Death-1(PD-1)
Last updated:
Abstract:
The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a programmed death-1 (PD-1) protein. The invention provides a PD-1-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the PD-1-binding agent to treat a cancer or an infectious disease.
Status:
Application
Type:
Utility
Filling date:
13 Jul 2020
Issue date:
3 Jun 2021